It is beyond doubt that the biotech industry has come a long way forward since its early days. The industry has witnessed innovative solutions, strategies, and new challenges.
The industry has been quite successful at redefining some of its earlier features. Yet, can we say the future is easy for the sector? Definitely not.
Some surveys indicate that the future could be tough for the industry.
READ MORE: Personalized Medicine, the Most Noteworthy Trend in 2023 Biotech?
The biotech sector is facing a difficult future, according to the 33rd edition of the Ernst & Young LLP (EY US) Beyond Borders study, as large pharma companies address innovation deficiencies and look for new revenue streams.
The authors of the research state that while reducing processes and increasing efficiency are essential at every stage of the business—from R&D to commercial—biotech will still be able to expand.
READ MORE: Gene Therapies, An Influential Biotech Trend for the U.S Biotech Industry 2023
The research, which provides an overview of the commercial performance of the biotech sector, identifies significant issues for leaders as well as obstacles the sector is now facing in this atypical business climate.
The global pandemic has pushed biotech research and uptake in the hopes that it would produce fresh remedies for pressing global problems.
However, the industry will have to overcome the challenge of innovation deficit as it progresses.
“Innovation is the engine that drives the biotech industry. While the approaching patent cliff is an unavoidable challenge, the pipeline continues to be very robust, and the pace of innovation continues to accelerate. If executives can prioritize streamlining processes and the ongoing investment in organic innovation and inorganic growth, they will set themselves up for future success,” informs Ashwin Singhania, Principal, EY-Parthenon.